EnEvolv, Inc., The Genome Engineering Company, engineers and licenses microorganisms to produce chemicals enzymes and small molecules for a variety of industries including specialty chemicals, food, energy, personal care, and pharmaceuticals. The Company's proprietary platform is built on Multiplex Automated Genome Engineering (MAGE) technology, developed by EnEvolv's co-founders, George Church and Farren Isaacs at Harvard. By treating the genome as the unit of engineering, enEvolv offers substantial advantage in speed, cost, and cellular engineering capabilities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/13/14 | $1,700,000 | Series A |
Cultivian Sandbox Venture Partners | undisclosed |
